EQ Jan 2025 7.500 call
| Previous close | 0.0500 |
| Open | N/A |
| Bid | 0.0500 |
| Ask | 2.3500 |
| Strike | 7.50 |
| Expiry date | 2025-01-17 |
| Day's range | 0.0500 - 0.0500 |
| Contract range | N/A |
| Volume | |
| Open interest | 10 |
Business WireEquillium to Participate in Upcoming Investor Conferences
LA JOLLA, Calif., July 02, 2024--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will be participating in the Leerink Partners Therapeutic Forum: I&I and Metabolism, as well as the JonesTrading Healthcare Seaside Summit.
Business WireEquillium to be included in the Russell Microcap® Index
LA JOLLA, Calif., June 12, 2024--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it expects to join the Russell Microcap Index at the conclusion of the 2024 Russell annual reconstitution, effective at the open of equity markets on Monday, July 1, according to a preliminary list of additions posted Friday, May 24.
Business WireEquillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
LA JOLLA, Calif., June 05, 2024--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that on May 31, 2024, the Compensation Committee of Equillium’s Board of Directors granted an inducement award consisting of a nonstatutory stock option to purchase 7,200 shares of common stock to a new employee under Equillium’s 2024 Inducement Plan. The Compensation Committee approve
